The Latest

  • An illustration for BioPharma Dive's deals database
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip
    Deep Dive

    Biotech M&A is on the upswing. Track the latest deals here.

    Biogen’s proposed acquisition of HI-Bio is the ninth buyout of an immune drug developer so far this year, outpacing even oncology M&A.

    Updated 11 hours ago
  • Data Analytics and business intelligence concept.
    Image attribution tooltip

    iStock / Worawut Prasuwan

    Image attribution tooltip
    Sponsored by Panalgo

    The ABCs of SDOH: Meaningful strategies to improve patient outcomes

    As biopharmaceutical and medical device companies increasingly recognize the impact of SDOH, a question emerges: how can these sponsors effectively integrate SDOH data into clinical trial recruitment and real-world evidence strategies?

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip
    News roundup

    Regeneron faces new biosimilar threats; an AI biotech lays off staff

    Today’s rundown also includes news of an expanded partnership for Boehringer Ingelheim and updates to emerging medicines from GSK and Bristol Myers. 

  • A person works in a laboratory at AltruBio.
    Image attribution tooltip
    Permission granted by AltruBio
    Image attribution tooltip
    Emerging biotech

    AltruBio lands up to $225M after shift to immune drug research

    Since pivoting from oncology, the startup has raised close to $300 million and advanced an ulcerative colitis drug into mid-stage testing.

  • Image attribution tooltip
    AstraZeneca
    Image attribution tooltip

    AstraZeneca sets sights on $80B in revenue by 2030

    The U.K. pharma expects to launch 20 new drugs by then, among them complex medicines for cancer as well as treatments for weight loss.

  • A headshot of Cyrus Mozayeni, CEO of Pheon Therapeutics.
    Image attribution tooltip
    Permission granted by Pheon Therapeutics
    Image attribution tooltip
    Emerging biotech

    Pheon rides wave of ADC interest with $120M financing

    CEO Cyrus Mozayeni said the company is taking a different approach than other developers of antibody-drug conjugates, though it’s keeping details close.

  • A thumbnail illustration for BioPharma Dive's IPO tracker
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip
    Deep Dive // Emerging biotech

    Biotech IPOs are the industry’s lifeblood. Track how they’re performing.

    Brain drug developer Rapport Therapeutics and radiopharma drugmaker Telix Pharmaceuticals are the first biotechs to seek an IPO in over two months.

    Updated May 20, 2024
  • A white sign with the word Lilly written in red stands outside of an office.
    Image attribution tooltip
    Scott Olson via Getty Images
    Image attribution tooltip

    Lilly partners with Aktis, deepening radiopharma investment

    The collaboration, which gives Lilly access to Aktis’ technology in return for $60 million, adds to a flurry of dealmaking in the radiopharma field.

  • An illustration of a neuron cell network on a black background.
    Image attribution tooltip
    koto_feja via Getty Images
    Image attribution tooltip

    Forbion-backed biotech Progentos debuts with $65M for MS drug

    Progentos says the money will go toward expanding its pipeline and pushing an experimental treatment for multiple sclerosis through "proof of concept” testing.

  • Image attribution tooltip
    Carl Court via Getty Images
    Image attribution tooltip

    European Commission, in ‘unprecedented’ move, declines to revoke approval of PTC Duchenne drug

    Rather than endorse the recommendation of the EMA, the commission called for a new review for Translarna that considers “the totality of the evidence” compiled to date.

  • Image attribution tooltip
    Elizabeth Regan / Industry Dive
    Image attribution tooltip

    Dyne shares jump on trial data for muscle disease drugs

    Updated study results for the biotech’s medicines for myotonic dystrophy Type 1 and Duchenne muscular dystrophy appeared to impress analysts and investors on Wall Street.

  • A stylized illustration of a "patent thicket" for Jonathan Gardner's Nov. 1 story on Amgen's Enbrel.
    Image attribution tooltip
    Adeline Kon / BioPharma Dive/BioPharma Dive
    Image attribution tooltip
    Deep Dive // Patent thickets

    Drug patents protect pharma profits. Track when they’ll expire here.

    Intellectual property is the foundation of the drug industry’s business model. This database will track key patent expiry dates for 30 top-selling medicines.

    Updated May 13, 2024
  • Large letters spelling Amgen are seen by a wall
    Image attribution tooltip
    Mario Tama via Getty Images
    Image attribution tooltip

    FDA approves Amgen drug for tough-to-treat form of lung cancer

    Imdelltra, a bispecific antibody targeting a protein called DLL3, is cleared for use following chemotherapy in treating extensive-stage small cell lung cancer.

    FDA
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip
    News roundup

    Erasca restructures; Novartis moves to complete MorphoSys deal

    The cancer biotech is laying off one-fifth of its staff and scrapping three drugs. Elsewhere, Novartis secured sufficient support for its $3 billion buyout and Bristol Myers won a new CAR-T approval.

  • Weight loss GLP-1
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip
    Obesity drugs

    Investors put $400M into biotech licensing obesity drugs from China

    The biotech, tentatively named Hercules CM Newco, has rights to three incretin drugs discovered by Jiangsu Hengrui Pharmaceuticals, two of which are in clinical testing.

  • A photo of a Biogen sign
    Image attribution tooltip
    Permission granted by Biogen
    Image attribution tooltip
    ALS drug development

    Biogen, Ionis shelve ALS drug following study failure

    While results indicated the drug works as intended, it didn’t have enough of an effect on a protein that’s become integral to many ALS research programs.

  • Image attribution tooltip
    Mario Tama via Getty Images
    Image attribution tooltip

    J&J to buy Proteologix and its dual-targeting antibody drugs for $850M

    The deal is part of a plan by J&J to build a portfolio of “differentiated” bispecific antibodies, an increasingly popular area of drug development. 

  • The logo of German pharmaceuticals and chemicals giant Bayer stands over Bayer corporate offices on September 14, 2016 in Berlin, Germany.
    Image attribution tooltip
    Sean Gallup via Getty Images
    Image attribution tooltip

    Detailed trial data show Bayer drug alleviates menopause symptoms

    Full study results disclosed ahead of a medical meeting showed elinzanetant consistently reduced the frequency and severity of hot flashes.

  • A Roche logo is seen on the side of a building.
    Image attribution tooltip
    Courtesy of Roche
    Image attribution tooltip
    Obesity drugs

    Roche keeps pace in obesity drug field with early study data

    A drug Roche acquired in a buyout of Carmot Therapeutics and that works similarly to Zepbound helped people lose nearly 19% of their body weight in a Phase 1 trial.

  • A white sign with the word Lilly written in red stands outside of an office.
    Image attribution tooltip
    Scott Olson via Getty Images
    Image attribution tooltip

    Lilly’s once-weekly insulin matches daily shots in late-stage tests

    The results, which showed Lilly’s drug was as effective at controlling blood sugar as standard injections, come as Novo Nordisk seeks approval for a competing once-weekly insulin.

  • A blurred photo of an empty laboratory
    Image attribution tooltip
    Ozankutsal via Getty Images
    Image attribution tooltip

    Bolt Biotherapeutics to lay off staff, abandon lead ADC candidate

    The company will cut its workforce by half and shuffle leadership as it discontinues testing of the drug trastuzumab imbotolimod.

  • An illustration of human lungs with a geometrical effect.
    Image attribution tooltip
    eranicle via Getty Images
    Image attribution tooltip

    Blackstone-backed biotech launches with up to $300M for immune drug

    Uniquity Bio emerged from stealth mode ready to begin Phase 2 trials of an antibody targeting the protein TSLP in asthma and COPD.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip
    News roundup

    Novo Holdings buys stake in life sciences tools company; BioMarin lays off 170

    The parent of Novo Nordisk is acquiring 60% ownership of Single Use Support, which specializes in handling of advanced therapies. Elsewhere, BioMarin and gene therapy developer Tenaya are cutting jobs.

  • A vial of Eisai and Biogen's Alzheimer's disease drug Leqembi
    Image attribution tooltip
    Courtesy of Eisai
    Image attribution tooltip
    New Alzheimer's drugs

    Eisai sets new revenue target for Alzheimer’s drug Leqembi

    The annual forecast, which comes as Eisai and Biogen have begun submitting a more convenient form of Leqembi for approval, looks “more realistic” than previous guidance, according to Jefferies analysts.

  • Image attribution tooltip
    Andreas Rentz via Getty Images
    Image attribution tooltip

    Bayer details layoffs as company shake-up continues

    The reduction of 1,500 roles in the first quarter is part of CEO Bill Anderson’s plan to shrink Bayer’s bureaucracy and “radically realign” its culture.

  • A man dressed in a suit looks at the camera in this headshot.
    Image attribution tooltip
    Permission granted by FogPharma
    Image attribution tooltip

    FogPharma, Artbio join forces to design a different radiopharma drug

    The biotechs aim to marry FogPharma’s polypeptide science with Artbio’s lead-based radiopharmaceutical technology in one of the industry’s hottest fields.